Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 2836 AL 2850

Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease

Ceyzériat K, Zilli T, Millet P, Frisoni GB, Garibotto V, Tournier BB.

Curr Alzheimer Res. 2020;17(2):112-125. doi: 10.2174/1567205017666200304085513.

Aβ-ganglioside interactions in the pathogenesis of Alzheimer's disease

Matsuzaki K.

Biochim Biophys Acta Biomembr. 2020 Aug 1;1862(8):183233. doi: 10.1016/j.bbamem.2020.183233. Epub 2020 Mar 3.

Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential

Mi Y, Qi G, Brinton RD, Yin F.

Antioxid Redox Signal. 2021 Mar 10;34(8):611-630. doi: 10.1089/ars.2020.8070. Epub 2020 Apr 21.

Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs

Ihara M, Saito S.

J Alzheimers Dis. 2020;74(4):1013-1028. doi: 10.3233/JAD-200049.

Contribution of the Presenilins in the cell biology, structure and function of γ-secretase

Escamilla-Ayala A, Wouters R, Sannerud R, Annaert W.

Semin Cell Dev Biol. 2020 Sep;105:12-26. doi: 10.1016/j.semcdb.2020.02.005. Epub 2020 Mar 4.

The Bewildering Effect of AMPK Activators in Alzheimer's Disease: Review of the Current Evidence

Assefa BT, Tafere GG, Wondafrash DZ, Gidey MT.

Biomed Res Int. 2020 Feb 18;2020:9895121. doi: 10.1155/2020/9895121. eCollection 2020.

TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology

Uddin MS, Kabir MT, Rahman MM, Mathew B, Shah MA, Ashraf GM.

J Pharm Pharmacol. 2020 Aug;72(8):1001-1012. doi: 10.1111/jphp.13244. Epub 2020 Mar 9.

Do infections have a role in the pathogenesis of Alzheimer disease?

Itzhaki RF, Golde TE, Heneka MT, Readhead B.

Nat Rev Neurol. 2020 Apr;16(4):193-197. doi: 10.1038/s41582-020-0323-9. Epub 2020 Mar 9.

Acetylcholinesterase: The "Hub" for Neurodegenerative Diseases and Chemical Weapons Convention

Cavalcante SFA, Simas ABC, Barcellos MC, de Oliveira VGM, Sousa RB, Cabral PAM, Kuča K, França TCC.

Biomolecules. 2020 Mar 7;10(3):414. doi: 10.3390/biom10030414.

Exploring the Promise of Targeting Ubiquitin-Proteasome System to Combat Alzheimer's Disease

Al Mamun A, Uddin MS, Kabir MT, Khanum S, Sarwar MS, Mathew B, Rauf A, Ahmed M, Ashraf GM.

Neurotox Res. 2020 Jun;38(1):8-17. doi: 10.1007/s12640-020-00185-1. Epub 2020 Mar 9.

Donepezil for dementia due to Alzheimer's disease

Govind N.

Br J Community Nurs. 2020 Mar 2;25(3):148-149. doi: 10.12968/bjcn.2020.25.3.148.

Nanoparticlized System: Promising Approach for the Management of Alzheimer's Disease through Intranasal Delivery

Bahadur S, Sachan N, Harwansh RK, Deshmukh R.

Curr Pharm Des. 2020;26(12):1331-1344. doi: 10.2174/1381612826666200311131658.

Research Progress on Alzheimer's Disease and Resveratrol

Yan Y, Yang H, Xie Y, Ding Y, Kong D, Yu H.

Neurochem Res. 2020 May;45(5):989-1006. doi: 10.1007/s11064-020-03007-0. Epub 2020 Mar 11.

Insulin mediated novel therapies for the treatment of Alzheimer's disease

Dubey SK, Lakshmi KK, Krishna KV, Agrawal M, Singhvi G, Saha RN, Saraf S, Saraf S, Shukla R, Alexander A.

Life Sci. 2020 May 15;249:117540. doi: 10.1016/j.lfs.2020.117540. Epub 2020 Mar 10.

Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease

Wei H, Zhang HL, Xie JZ, Meng DL, Wang XC, Ke D, Zeng J, Liu R.

Curr Med Sci. 2020 Feb;40(1):1-8. doi: 10.1007/s11596-020-2140-1. Epub 2020 Mar 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias